NovoCure Ltd
Close on Oct 19, 2026
- Market cap
- $1.73B
- P/E (TTM)
- –
- Dividend yield
- –
About NovoCure
Surgical & Medical Instruments & Apparatus, SIC 3841
Novocure is an oncology company that develops and commercializes therapies based on Tumor Treating Fields, a proprietary technology using electric fields to disrupt cancer cell division. Its primary commercial medical devices include Optune Gio, Optune Lua, and Optune Pax. These portable systems treat adult patients with solid tumor malignancies, specifically glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma, and locally advanced pancreatic cancer. The company delivers products directly to patients or through hospitals, following prescriptions from certified healthcare providers.
Executive management and operational control reside in Switzerland, while legal incorporation is in Jersey, supported by operating centers worldwide. The business markets devices across multiple countries, primarily the United States, Germany, France, and Japan, with additional commercial distribution in Greater China through a regional partner. As of late 2025, the company maintains a global sales force of 217 personnel.
Summary of the business section of NovoCure's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NovoCure Ltd
- Founded
- 2000
- Headquarters
- St. Helier, Jersey
- Address
- No. 4 The Forum, Grenville Street
- Phone
- 44 (0)15 3475 6700
- Employees
- 1,605, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Fiscal year ends
- December 31
- Auditor
- KOST FORER GABBAY & KASIERERA Member of EY Global, Israel
Stock & identifiers
- Ticker
- NVCR
- Exchange
- Nasdaq
- Shares outstanding
- 116M, Jul 17, 2026
- Public float
- $994.96M, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1645113
- CUSIP
- G6674U108
- ISIN
- USG6674U1081
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| William F. Doyle | Executive Chairman, Director | 681,167 |
| Frank X. Leonard | Chief Executive Officer | 461,425 |
| Michal Nath Puri | Chief Human Resources Officer | 203,227 |
| Arye Barak Ben | General Counsel | 243,752 |
| Christoph Brackmann | Chief Financial Officer | 182,842 |
| Nicolas Leupin | Former Chief Medical Officer | 102,979 |
| Uri Weinberg | Chf Medical and Innovation Ofr | 267,190 |
| Ashley Cordova | Former Chief Executive Officer | 422,570 |
| Mukund Paravasthu | Chief Operating Officer | 72,832 |
| Asaf Danziger | Director | 416,742 |
| Martin J. Madden | Director | 30,668 |
| Timothy J. Scannell | Director | 25,898 |
| W. Anthony Vernon | Director | 209,267 |
| Gabriel Leung | Director | 101,109 |
| Jeryl L. Hilleman | Director | 25,471 |
| David Hung | Director | 32,075 |
| Kristin Stafford | Director | 22,934 |
| Allyson J. Ocean | Director | 22,934 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr.Danziger | $0 | $0 | $4.06M | $7 | $125 |
| FY2025 Mr.Leornard | $6.98M | $62.30K | $4.06M | $7 | $125 |
| FY2025 Ms.Cordova | $13.20M | -$4.50M | $4.06M | $7 | $125 |
| FY2024 Mr. Leonard | $1.54M | $796.24K | $5.44M | $35 | $118 |
| FY2023 Mr. Leonard | $1.52M | -$5.23M | $5.47M | $18 | $119 |
| FY2022 Mr. Leonard | $2.28M | $2.08M | $6.48M | $87 | $114 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 1,605 employees, compared to 1,488 employees as of December 31, 2024.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 31, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 23, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |